Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib access protocol for advanced renal cell carcinoma
ACTRN12606000140550Phase 2Completed
- Sponsor
- Austin Health
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by Austin Health. Primary endpoint: Progression of disease. Started Jun 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12606000140550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000140550.